US Medicare sets outpatient rate for Yescarta reimbursement


REUTERS: Medicare, the U.S. government healthcare program for the elderly and disabled, will pay hospitals close to its standard mark-up rate for administering cell therapy Yescarta for cancer outpatients, who will have a co-payment of nearly US$80,000, according to the Centers for Medicare & Medicaid Services . Additional Medicare reimbursement for inpatients has been requested by Yescarta maker Gilead Sciences Inc and Novartis AG, which makes Kymriah, a similar therapy.



from Biotech News